Solorank.ai
Login

Cached score snapshot

US.VRTX · Vertex Pharmaceuticals

110分制 63.4/110；5D動能v2 3/50；排序分 66.4/160

Back to ranking Open volume snapshot
Ranking score 66.4/160
Main score 63.4/110
5D momentum v2 3/50
Rank #140
Setup grade F 30.3

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 30.3 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-05 07-21 09-01 09-22 10-12 $416.10$544.40$672.70 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.318 · anchors 120 +1.35% -0.59% / +3.31% 65% 1.3% Actual +2.47% · vs median +1.12% · inside 25-75 band
30D observation +10.99% +2.67% / +15.66% 80% 7.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.56% -1.35% / +2.45% 58.8% 1.9% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-05 → 2026-10-12 · 119 archived points · 4 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 66.4
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 63.4/110 (觀望)
5D momentum v2 3/50 (弱)
Score with momentum v2 66.4/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 525.536
ma50 502.4064
close 544.52
prevClose 541.69
avgVolume20 1184630
volumeRatio 1.01
changePercent 0.52

Metrics snapshot

close 544.52
volume 1197308
changePercent 0.52

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 63.4/110
Main rating 觀望
5D momentum v2 3/50
Score with momentum v2 66.4/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.8/5 · 良好
Dimension score 3.8/5
Dimension grade 良好

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.75
debtPoints 0.5
marginPoints 0.75
turnoverUsdM 651.9582
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 11.6/20 · 較差
Dimension score 11.6/20
Dimension grade 較差

Sub-items

cmfPoints 1.6
mfiPoints 1.6
obvPoints 2.4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.VRTX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 11.4/15 · 良好
Dimension score 11.4/15
Dimension grade 良好

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 14.43

trend

score 2.8

details

qqq

ma20 718.7765
ma50 711.5868
name QQQ
close 716.76
points 1.4

spy

ma20 769.685
ma50 754.3614
name SPY
close 767.05
points 1.4
source twelvedata+fred
atrPct 2.474
atrPoints 3
cciPoints 3.2
vixPoints 2.4
marketTrendPoints 2.8

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 7.6/10 · 良好
Dimension score 7.6/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.474
turnoverUsdM 651.9582
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.6

stopLevels

symbol US.VRTX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 517.5768

strength_details

ma_score 1.5
atr_score 2
rsi_score 2
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.6
stop_loss_percent 4.9
take_profit_price 587.0005
target_multiplier 2.2
technical_strength 2.15
take_profit_percent 7.8
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.5764
stopLossPercent 4.9481
diversificationPoints 2

技術信號 — 21/30 · 良好
Dimension score 21/30
Dimension grade 良好

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 1.5
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 1.5
vcp_reason 跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y

vcp_metrics

up_days 5
vol_ref 1235076.6667
down_days 4
vcp_ready false
above_ma50 true
avg_vol_10 1029000
avg_vol_20 1200290
avg_vol_30 1235076.6667
range_pct_10 0.0976
range_pct_20 0.1656
range_pct_30 0.1666
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 0.8331
dist_to_20d_high 0.0201
down_shrink_days 4
breakout_level_20d 555.69
vcp_breakout_confirm true
contraction_ratio_10_30 0.5862
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.4
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 1.2

情緒分析 — 6/10 · 一般
Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 4
sentimentScoreRaw 1.2

sentimentData

raw {"id":141279342,"url":"https://finnhub.io/api/news?id=54e185545576cdb9dc6d734866d58e0390b06540a7324cc4bfacb43aecc1896b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]","category":"company","datetime":1786751639,"headline":"Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?"}, {"id":141279343,"url":"https://finnhub.io/api/news?id=121dbbc0dd24c01e2e2cbe20976d9967255da4cc4f625d608de73f25a3e6e9ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...","category":"company","datetime":1786749229,"headline":"Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?"}, {"id":141279351,"url":"https://finnhub.io/api/news?id=68de4dec7cef46611e52bc7bd83708d22013031b64ec4eddd23a06dc1e657631","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurchase program. See our latest analysis for Vertex Pharmaceuticals. The latest updates on guidance and buybacks come after a solid run in Vertex Pharmaceuticals' stock, with a 90 day share price return of 18.19% and a 1 year total shareholder return of 31.48%. This suggests momentum has been...","category":"company","datetime":1786741725,"headline":"Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance"}, {"id":141181019,"url":"https://finnhub.io/api/news?id=25154402fb3d0f222a8033f7866218d6e3ae8c5b8861a9206afa0c14ca55b514","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Revenue hit $3.3 billion with guidance raised on strong newer product growth.","category":"company","datetime":1786411788,"headline":"Vertex (VRTX) Q2 2026 Earnings Call Transcript"}, {"id":141175445,"url":"https://finnhub.io/api/news?id=ded9ed4f3587c20b78610c4ba38b8ecf5e094890c470cb2c855d3017e81055fd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex’s efforts to broaden its pipeline while easing pressure on its core franchise. We’ll now examine how...","category":"company","datetime":1786374853,"headline":"Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?"}, {"id":141111809,"url":"https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.","category":"company","datetime":1785855420,"headline":"VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"}, {"id":141110156,"url":"https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.","category":"company","datetime":1785852000,"headline":"VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"}, {"id":141107841,"url":"https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...","category":"company","datetime":1785841838,"headline":"Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"}
raw_source {"id":141355051,"url":"https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.","category":"company","datetime":1788173434,"headline":"Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"}, {"id":141337932,"url":"https://finnhub.io/api/news?id=9e15849a5291795973d1ff60d89173fba9ef89cac40c0b1eef7ddc20906a3b06","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a market","category":"company","datetime":1787855435,"headline":"If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today"}, {"id":141329219,"url":"https://finnhub.io/api/news?id=9d227bb9788bbec12f4ada19baf0f9a5b3442ec7c4b503cb31198016994d61bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, August 26, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences.","category":"company","datetime":1787774400,"headline":"Vertex to Participate in Upcoming September Investor Conferences"}, {"id":141329210,"url":"https://finnhub.io/api/news?id=494fc4a7e7e95660a751b27eb0ae630285a8b5d40336969ed3193c07198cabfc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.","category":"company","datetime":1787751180,"headline":"Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock"}, {"id":141329220,"url":"https://finnhub.io/api/news?id=2efc1eb2f1504efc935bad39ac81fc43191acc9d8325e302cef134c0b83a88df","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.","category":"company","datetime":1787736673,"headline":"2 Large-Cap Stocks to Research Further and 1 We Question"}, {"id":141329221,"url":"https://finnhub.io/api/news?id=bb83f2f0a7c2ff81c357b015f34cc9609eeb516382bc97e2c709c50480540cae","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.","category":"company","datetime":1787584800,"headline":"Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide"}, {"id":141270357,"url":"https://finnhub.io/api/news?id=c860ce08d4e08f9258062cb8d66f67f20b4b52147ffd6129f0e478139ec5544b","image":"https://cdn.benzinga.com/files/images/story/2026/08/21/Expert-Sees-Lower-Payments.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).","category":"company","datetime":1787300370,"headline":"Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’"}, {"id":141279339,"url":"https://finnhub.io/api/news?id=8d9cbc0bd104b45cfccc7cbd2c068ed28335b859cc9c4ef376db8c67375a427e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Don't bet against Vertex Pharmaceuticals in cystic fibrosis.","category":"company","datetime":1787259000,"headline":"Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead"}, {"id":141279340,"url":"https://finnhub.io/api/news?id=155b9bfb8c208e5ddbce0b12f61eae388a3c391b302784352be725c1e6ca15da","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.","category":"company","datetime":1787213930,"headline":"Are Wall Street Analysts Bullish on Vertex Stock?"}, {"id":141265012,"url":"https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...","category":"company","datetime":1787139000,"headline":"HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"}, {"id":141279349,"url":"https://finnhub.io/api/news?id=5023715a3073c930cbeb889de0d9f0c715e9eb1a27489a9f88dc6339148f07f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"ANT survey delivers a 3D subsurface view that reinforces the Robinsons River geological model and de-risks the next stage of technical workVANCOUVER, British Columbia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce the final results of the Ambient Noise Tomography (“ANT”) survey completed at the Company's 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south","category":"company","datetime":1787058000,"headline":"Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt Project"}, {"id":141279350,"url":"https://finnhub.io/api/news?id=c16319e9e5a0594ce94d91a58aae67103c60bf48c8111a1e761a7abb904d849e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.","category":"company","datetime":1787050653,"headline":"3 Cash-Producing Stocks on Our Watchlist"}, {"id":141279342,"url":"https://finnhub.io/api/news?id=54e185545576cdb9dc6d734866d58e0390b06540a7324cc4bfacb43aecc1896b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]","category":"company","datetime":1786751639,"headline":"Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?"}, {"id":141279343,"url":"https://finnhub.io/api/news?id=121dbbc0dd24c01e2e2cbe20976d9967255da4cc4f625d608de73f25a3e6e9ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...","category":"company","datetime":1786749229,"headline":"Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?"}, {"id":141279344,"url":"https://finnhub.io/api/news?id=ad845cd38300618d82185831e5a6bc71375dd3819365cbdfe4d132fbc0e16813","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The drugmaker should significantly mitigate its most important risk as it develops new products.","category":"company","datetime":1786742400,"headline":"Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More"}, {"id":141279351,"url":"https://finnhub.io/api/news?id=68de4dec7cef46611e52bc7bd83708d22013031b64ec4eddd23a06dc1e657631","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurchase program. See our latest analysis for Vertex Pharmaceuticals. The latest updates on guidance and buybacks come after a solid run in Vertex Pharmaceuticals' stock, with a 90 day share price return of 18.19% and a 1 year total shareholder return of 31.48%. This suggests momentum has been...","category":"company","datetime":1786741725,"headline":"Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance"}, {"id":141278992,"url":"https://finnhub.io/api/news?id=dd9febaaffadd17c6453617b941b5caf27cdeb0d05ef7fba593bec5de3ada72d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...","category":"company","datetime":1786730820,"headline":"BofA biotech scorecard: Two buys and odd one out"}, {"id":141219761,"url":"https://finnhub.io/api/news?id=da70f751bbe83141d4f27ef4146624b19996919da2578c396c2740a8e6ab5c54","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals has a market","category":"company","datetime":1786708843,"headline":"$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today"}, {"id":141216339,"url":"https://finnhub.io/api/news?id=c3f0aff57d50e4a1dd7a3be345d26477178a91b70e18cd1e6169d1e527dc0954","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203426973/image_2203426973.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX stock is a Buy.","category":"company","datetime":1786700403,"headline":"Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)"}, {"id":141205416,"url":"https://finnhub.io/api/news?id=f9ed0860d21fac5b45889bb5f7d101977f12066b6c9bab95f6a065bf9ebbfa7a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.","category":"company","datetime":1786628127,"headline":"Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public"}, {"id":141201319,"url":"https://finnhub.io/api/news?id=53aa7945d94041f79fc3c71da1078689d1f51f26eefe2f5010464d79b2c6af29","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid","category":"company","datetime":1786546972,"headline":"Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says"}, {"id":141201320,"url":"https://finnhub.io/api/news?id=94ae668ac83f9d0c31f3ea05ec0b9d4f8d9080150624d1764bb6bc404342d9d4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […]","category":"company","datetime":1786506091,"headline":"One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses"}, {"id":141201321,"url":"https://finnhub.io/api/news?id=6e1eb33508d1e98d3f2908639df7e4bb95e526c95178197694a844bc74661f7f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to “the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,” while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK a","category":"company","datetime":1786498882,"headline":"5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call"}, {"id":141195154,"url":"https://finnhub.io/api/news?id=3df760a6590509c410b1316b0c369b2cdec8dbbe87802b2bd472f31783084fc2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.","category":"company","datetime":1786456860,"headline":"4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year"}, {"id":141181019,"url":"https://finnhub.io/api/news?id=25154402fb3d0f222a8033f7866218d6e3ae8c5b8861a9206afa0c14ca55b514","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Revenue hit $3.3 billion with guidance raised on strong newer product growth.","category":"company","datetime":1786411788,"headline":"Vertex (VRTX) Q2 2026 Earnings Call Transcript"}, {"id":141177336,"url":"https://finnhub.io/api/news?id=33fd1ad98365e1c3dbe7cfb12732e37392475fc9a30b95ecb5247d60db37ef4c","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"VRTX","summary":"Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.","category":"company","datetime":1786388701,"headline":"Discover which S&P500 stocks are making waves on Monday."}, {"id":141176731,"url":"https://finnhub.io/api/news?id=f952c743779714457b4eaa6ff9b23dc5fe72cec6eb0b9823761ee130a6bb028f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.","category":"company","datetime":1786382317,"headline":"SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?"}, {"id":141175993,"url":"https://finnhub.io/api/news?id=591168258f393e68563e6da9dea3f941c18dfd48941990aa7fa198e9025a1e5b","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"VRTX","summary":"Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.","category":"company","datetime":1786379701,"headline":"Explore the top gainers and losers within the S&P500 index in today's session."}, {"id":141176732,"url":"https://finnhub.io/api/news?id=bd21004d940cdf0607d4305d000bc04b7354225c4f16c854cd15d938f7a4a3e1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.","category":"company","datetime":1786377660,"headline":"Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low"}, {"id":141175444,"url":"https://finnhub.io/api/news?id=345e622f9b0fd39685338ae62271fcae679f190bddb55d205a2d0875784c7044","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Sionna's disappointing trial removes an immediate competitive threat to the franchise generating most of Vertex's revenue.","category":"company","datetime":1786377337,"headline":"Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails"}, {"id":141175445,"url":"https://finnhub.io/api/news?id=ded9ed4f3587c20b78610c4ba38b8ecf5e094890c470cb2c855d3017e81055fd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex’s efforts to broaden its pipeline while easing pressure on its core franchise. We’ll now examine how...","category":"company","datetime":1786374853,"headline":"Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?"}, {"id":141175245,"url":"https://finnhub.io/api/news?id=a973147764263f3bdc864ad125bd056f1b6a36b2ab0a6f63d654ad0875da6be9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.","category":"company","datetime":1786371120,"headline":"This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News."}, {"id":141174376,"url":"https://finnhub.io/api/news?id=6b4e91291819cf3182cb35b176bf378d8c88e994c518a2edd32e1635e1722681","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.","category":"company","datetime":1786368173,"headline":"Why Vertex Pharma Popped, As A Key Rival Plummeted 90%"}, {"id":141173955,"url":"https://finnhub.io/api/news?id=8f8a6c94e14cda994096b4ea274ea3ef41e64e688ce7867132f30f540487144b","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"VRTX","summary":"As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.","category":"company","datetime":1786365301,"headline":"Get insights into the top movers in the S&P500 index of Monday's pre-market session."}, {"id":141176733,"url":"https://finnhub.io/api/news?id=e621a61ac2fd6f06e6f8dfde3327b9a465a9d264ddc5f3496d75a321a713b950","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.","category":"company","datetime":1786364579,"headline":"Sionna cystic fibrosis drug fails key trial, removing threat to Vertex"}, {"id":141163533,"url":"https://finnhub.io/api/news?id=3b7a86f6ceb88fe11df34224171d2e64d74b5e8b7d5f7a718f923ea58fe91d9c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Tweedy Browne’s Q2 2026 13F: $1.32B portfolio, top holdings & new Zoetis stake, plus trims/exits and concentration insights—read now.","category":"company","datetime":1786229949,"headline":"Tracking Tweedy Browne Portfolio - Q2 2026 Update"}, {"id":141150935,"url":"https://finnhub.io/api/news?id=f30205fda5e3671faae31aaf11b68289bc37bc3003af8d9080eae74361b10542","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"This risk is weighing on the stock.","category":"company","datetime":1786126800,"headline":"Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?"}, {"id":141148212,"url":"https://finnhub.io/api/news?id=f1429036e90b90226a0f1548de75810532846ed909768a41040c55c430c961bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.","category":"company","datetime":1786117197,"headline":"What Insmed Stock's Premium Is Actually Buying"}, {"id":141135446,"url":"https://finnhub.io/api/news?id=fd1d07072af0353df58d8c6462fe44867241410e634aa7fe7a706972fa6edc43","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"IONQ posts a wider-than-expected Q2 loss but tops revenue estimates, raises its 2026 revenue outlook and sees shares rise after the results.","category":"company","datetime":1786027140,"headline":"IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises"}, {"id":141134178,"url":"https://finnhub.io/api/news?id=d3341145831fa1164ba72987649fc3f9cde6dfde5df1d47e24be44aed8cc7b65","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Study confirms western salt structure, identifies an eastern exploration target and establishes a staged technical pathway for further evaluationVANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release dated July 16, 2026, that it has received the final technical study prepared by Lonquist Field Service (Canada), ULC (“Lonquist”) for the Company’s Robinson","category":"company","datetime":1786017600,"headline":"Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project"}, {"id":141131676,"url":"https://finnhub.io/api/news?id=42acecf7bad1baa7ec04cb7ac59418a1c1004daf4cddd4cce6da65363ef901db","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.","category":"company","datetime":1785992501,"headline":"AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ..."}, {"id":141129231,"url":"https://finnhub.io/api/news?id=dcdf3ce3fb9a9978376d50e78da86431a8757aa1e827d9ec985228c198f4b841","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol","category":"company","datetime":1785967428,"headline":"AbCellera Biologics Q2 Earnings Call Highlights"}, {"id":141128774,"url":"https://finnhub.io/api/news?id=2a2a2d7e0c3b0c4acf97cdb30edff26305271e2d709137a8518fb82aaeb34cfe","image":"","source":"Benzinga","related":"VRTX","summary":"Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.","category":"company","datetime":1785938692,"headline":"Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565"}, {"id":141120403,"url":"https://finnhub.io/api/news?id=f62b2e86c4216e2bda2377255cef430a7f277cbdefbb4b3b2c17c9278e69b758","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc","category":"company","datetime":1785927600,"headline":"Entrada Therapeutics Reports Second Quarter 2026 Financial Results"}, {"id":141121678,"url":"https://finnhub.io/api/news?id=5248f37b608df4175afdacfec21505a887b9d7e62e088904934c0a4a097c8b4d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288169175/image_2288169175.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.","category":"company","datetime":1785924544,"headline":"CRISPR: \"Strong Buy\" CASGEVY Sales Growth And In Vivo Expansion With CTX310"}, {"id":141128775,"url":"https://finnhub.io/api/news?id=4a00fc07417e00a900782dede2c3227b5bb2ffd5494048eb5e0a007a66482462","image":"","source":"Benzinga","related":"VRTX","summary":"Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.","category":"company","datetime":1785922255,"headline":"Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617"}, {"id":141111807,"url":"https://finnhub.io/api/news?id=e47001faa115166263a442f28230abdba42b95d19b8edb04e4fd9ecec1553469","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa","category":"company","datetime":1785863115,"headline":"Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says"}, {"id":141111808,"url":"https://finnhub.io/api/news?id=1779ffa16d4cf28c1b259ac324be9f15ee814476b807b5bf97951a8231ca3e17","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength","category":"company","datetime":1785859337,"headline":"Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says"}, {"id":141110155,"url":"https://finnhub.io/api/news?id=ab934a24772cacbc2444176e33fe2e26a3432801ece501642cda46733319fe6f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment.","category":"company","datetime":1785855630,"headline":"How Vertex Regained Its Footing On A Competitor's Bullish Report"}, {"id":141111809,"url":"https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.","category":"company","datetime":1785855420,"headline":"VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"}, {"id":141110509,"url":"https://finnhub.io/api/news?id=f6f657f73b56d365c3988923bf6a3d9124e87491e39b6391d0a32defb58016c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.","category":"company","datetime":1785855360,"headline":"CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates"}, {"id":141110156,"url":"https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.","category":"company","datetime":1785852000,"headline":"VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"}, {"id":141120404,"url":"https://finnhub.io/api/news?id=536ca1939192aa75d5e6bab55534f6b569982fd11bc66824814b4cc31c74a4a9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call","category":"company","datetime":1785846600,"headline":"Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary"}, {"id":141128776,"url":"https://finnhub.io/api/news?id=a0e8acf95ce40887b103881fce5237ca4516cca5aecd8d5b7c448a54203438f4","image":"","source":"Benzinga","related":"VRTX","summary":"TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.","category":"company","datetime":1785846489,"headline":"TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550"}, {"id":141111811,"url":"https://finnhub.io/api/news?id=e0958b66343c41ec1dc90eccdc735fecb25accfdb235add8df6547d345ab61de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics \"looms large\" over Vertex.","category":"company","datetime":1785845940,"headline":"Vertex’s biggest overhang: a rival 50 times smaller"}, {"id":141107841,"url":"https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...","category":"company","datetime":1785841838,"headline":"Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"}, {"id":141107179,"url":"https://finnhub.io/api/news?id=06027c260ce9de9f61eb87edc3fd3f074dda0e76b30bcca2da7b0e57104fa68b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...","category":"company","datetime":1785834837,"headline":"Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands"}, {"id":141110584,"url":"https://finnhub.io/api/news?id=83f00ed155351fa091931ebd6f19d490a2410a74beb0fca26cc0781a757d8552","image":"","source":"Benzinga","related":"VRTX","summary":"Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.","category":"company","datetime":1785831893,"headline":"Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595"}, {"id":141107416,"url":"https://finnhub.io/api/news?id=79c24c254426f5197e92c42652e8d662216c9656ed34db5290a7b518a70f7c0b","image":"","source":"SeekingAlpha","related":"VRTX","summary":"","category":"company","datetime":1785826663,"headline":"Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story"}, {"id":141106171,"url":"https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.","category":"company","datetime":1785820106,"headline":"Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."}, {"id":141105354,"url":"https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...","category":"company","datetime":1785798598,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"}, {"id":141104289,"url":"https://finnhub.io/api/news?id=c7c1bac8a4be7e1bca887af4abc9e92a06d03ce636155d166171dc8851c4e126","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra","category":"company","datetime":1785798229,"headline":"Vertex Pharmaceuticals Q2 Earnings Call Highlights"}, {"id":141105291,"url":"https://finnhub.io/api/news?id=cd71711e25cb163c9f05f483851c9f5b6b7eb81c55fa46d409773ec5676efefb","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"2026-08-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2026 Q2 earnings call.","category":"company","datetime":1785798079,"headline":"Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation"}, {"id":141104290,"url":"https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","category":"company","datetime":1785792601,"headline":"Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"}, {"id":141104291,"url":"https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785792003,"headline":"Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"}, {"id":141103107,"url":"https://finnhub.io/api/news?id=98a2abcf301231bc0d0aaead7b8926e9c78fdfcb82c76cbbb0cc6e889ba5bb06","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.","category":"company","datetime":1785790435,"headline":"Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason"}, {"id":141103108,"url":"https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.","category":"company","datetime":1785789407,"headline":"Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"}, {"id":141103109,"url":"https://finnhub.io/api/news?id=c2b5656a468d8791f71fe09a62a59cf02bfd34ac2e88a2aafd4178787e8d1233","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumor","category":"company","datetime":1785787500,"headline":"Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update"}, {"id":141103110,"url":"https://finnhub.io/api/news?id=b906634ef71b39efd517bbbaafd8f51cefd4da9cb3e99c193c693beb458b10fa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, August 03, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.","category":"company","datetime":1785787260,"headline":"Vertex Reports Second Quarter 2026 Financial Results"}, {"id":141102404,"url":"https://finnhub.io/api/news?id=939a925a360f140b82437bcf1c066f9578c7f6d8d02242dd6344b422c5f7a75f","image":"","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.","category":"company","datetime":1785772904,"headline":"Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est"}, {"id":141102405,"url":"https://finnhub.io/api/news?id=d851715324594ca0a83a36932e5f194d1100c4a171088992edaa84adad7f327d","image":"","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last","category":"company","datetime":1785772886,"headline":"Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate"}, {"id":141101633,"url":"https://finnhub.io/api/news?id=210dc9eadb0f1e641b405b20d701188a86b5d7a5db961e15cc5ee67a2573203c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231767274/image_2231767274.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Big Tech's earnings reports laid bare a growing divide in the market's appetite for AI spending. Investors now focus on results from industrials, health care, consumer staples/discretionary.","category":"company","datetime":1785766800,"headline":"Divided Tech, Divided Fed: Navigating AI Capex Scrutiny And Mixed Macro Signals"}, {"id":141098887,"url":"https://finnhub.io/api/news?id=48d0b35462c58b56f76fb282a857a48a7324ea7d8a8bec1032ce82a8f07a63bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the","category":"company","datetime":1785755481,"headline":"Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up"}, {"id":141099604,"url":"https://finnhub.io/api/news?id=0b813f41b7078cecf12b4aafa9a2ca131b75aa021fa9c19c50adbd14d08635cb","image":"https://cdn.benzinga.com/files/images/story/2026/08/03/TysonFoods.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.","category":"company","datetime":1785724052,"headline":"Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday"}, {"id":141100201,"url":"https://finnhub.io/api/news?id=bad502596ada943e824fa1a41cadb663072846cc663445ce8eab7c42d8dbcca9","image":"https://cdn.benzinga.com/files/images/story/2026/08/03/Fear-and-Greed.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.","category":"company","datetime":1785723704,"headline":"Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone"}, {"id":141091494,"url":"https://finnhub.io/api/news?id=fab83185dfc322c5138a32b43f26849a509ecd83026c58227dad50ddfd0cb7aa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for.","category":"company","datetime":1785645417,"headline":"Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 4
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 76
discarded_article_count 62
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.8 5/110 76% 3.8
資金流 11.6 20/110 58% 11.6
市場環境 11.4 15/110 76% 11.4
催化劑 2 20/110 10% 2
風險管理 7.6 10/110 76% 7.6
技術信號 21 30/110 70% 21
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 3/50
ret_5d -0.0056
max_score 50
max_total 50
raw_total 3
vcp_bonus 0
vol_ratio 0.9975
ret_points 0
vol_points 0
range_ratio 1.0043
volat_points 0
day_range_pct 0.0267
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.474
turnoverUsdM 651.9582
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.6

stopLevels

symbol US.VRTX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 517.5768

strength_details

ma_score 1.5
atr_score 2
rsi_score 2
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.6
stop_loss_percent 4.9
take_profit_price 587.0005
target_multiplier 2.2
technical_strength 2.15
take_profit_percent 7.8
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.5764
stopLossPercent 4.9481
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.8/5分
資金流分析總分: 11.6/20分
市場環境分析總分: 11.4/15分
催化劑分析: 2/20分
風險管理總分: 7.6/10分
技術信號分析總分: 21/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 71.43
atr
atr 13.4716
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.47
cci
rule Cursor_18.24 CCI bands
level 適中偏強
score 8
value 54.12
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0188
kdj
d 77.02
j 53.98
k 69.34
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 40.61
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 6
trend 有流入
value 19114608
recentSlope 177770.8
previousSlope 467510
rsi
value 56.76
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 531.3817
position SAR喺價下
distancePct 2.41
previousTrend 上升
ma50
value 502.4064
macd
macd 15.7684
trend 強烈看漲
signal 15.2074
histogram 0.561
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 522.5111
position 連續5日>VWAP
consecutiveAbove 19
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.01
score 6
avgVolume 1184630
currentVolume 1197308
derived
ma20 525.536
ma50 502.4064
prevClose 541.69
avgVolume10 1037611
avgVolume20 1184630
changePercent 0.52
avgVolumeForScore 1184630
ma_cross
ma20 525.536
ma50 502.4064
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 521.846
prevMa50 500.5486
spreadPct 4.6
isVolumeBreakout false
bollinger
lower 478.0385
upper 573.0335
position 上半部
rsi_short
value 41.28
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.01

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.474032084256516,
        "turnoverUsdM": 651.9581761061601,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.VRTX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 517.5768,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.6,
      "stop_loss_percent": 4.9,
      "take_profit_price": 587.0005,
      "target_multiplier": 2.2,
      "technical_strength": 2.15,
      "take_profit_percent": 7.8
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.5763740595029545,
    "stopLossPercent": 4.948064168513032,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 66.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 63.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 525.536,
    "ma50": 502.4064,
    "close": 544.52,
    "prevClose": 541.69,
    "avgVolume20": 1184630,
    "volumeRatio": 1.01,
    "changePercent": 0.52
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.005606402293335977,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.9975156003965708,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.0042667142004398,
      "volat_points": 0,
      "day_range_pct": 0.026724343395124493,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 66.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 76,
        "contribution": 3.8
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 11.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 76,
        "contribution": 11.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 21,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 70,
        "contribution": 21
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 63.4,
    "details": [
      "基本面分析總分: 3.8/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 11.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 21/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.8,
      "資金流": 11.6,
      "市場環境": 11.4,
      "情緒分析": 6,
      "技術信號": 21,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 651.9581761061601,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VRTX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.43
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 718.7765020000002,
                "ma50": 711.5868006399995,
                "name": "QQQ",
                "close": 716.76001,
                "points": 1.4
              },
              "spy": {
                "ma20": 769.6849949,
                "ma50": 754.36140122,
                "name": "SPY",
                "close": 767.049988,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.474032084256516,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141279342,
                "url": "https://finnhub.io/api/news?id=54e185545576cdb9dc6d734866d58e0390b06540a7324cc4bfacb43aecc1896b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]",
                "category": "company",
                "datetime": 1786751639,
                "headline": "Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?"
              },
              {
                "id": 141279343,
                "url": "https://finnhub.io/api/news?id=121dbbc0dd24c01e2e2cbe20976d9967255da4cc4f625d608de73f25a3e6e9ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...",
                "category": "company",
                "datetime": 1786749229,
                "headline": "Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?"
              },
              {
                "id": 141279351,
                "url": "https://finnhub.io/api/news?id=68de4dec7cef46611e52bc7bd83708d22013031b64ec4eddd23a06dc1e657631",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurchase program. See our latest analysis for Vertex Pharmaceuticals. The latest updates on guidance and buybacks come after a solid run in Vertex Pharmaceuticals' stock, with a 90 day share price return of 18.19% and a 1 year total shareholder return of 31.48%. This suggests momentum has been...",
                "category": "company",
                "datetime": 1786741725,
                "headline": "Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance"
              },
              {
                "id": 141181019,
                "url": "https://finnhub.io/api/news?id=25154402fb3d0f222a8033f7866218d6e3ae8c5b8861a9206afa0c14ca55b514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Revenue hit $3.3 billion with guidance raised on strong newer product growth.",
                "category": "company",
                "datetime": 1786411788,
                "headline": "Vertex (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141175445,
                "url": "https://finnhub.io/api/news?id=ded9ed4f3587c20b78610c4ba38b8ecf5e094890c470cb2c855d3017e81055fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex’s efforts to broaden its pipeline while easing pressure on its core franchise. We’ll now examine how...",
                "category": "company",
                "datetime": 1786374853,
                "headline": "Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?"
              },
              {
                "id": 141111809,
                "url": "https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.",
                "category": "company",
                "datetime": 1785855420,
                "headline": "VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"
              },
              {
                "id": 141110156,
                "url": "https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.",
                "category": "company",
                "datetime": 1785852000,
                "headline": "VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"
              },
              {
                "id": 141107841,
                "url": "https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...",
                "category": "company",
                "datetime": 1785841838,
                "headline": "Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"
              }
            ],
            "raw_source": [
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141337932,
                "url": "https://finnhub.io/api/news?id=9e15849a5291795973d1ff60d89173fba9ef89cac40c0b1eef7ddc20906a3b06",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1787855435,
                "headline": "If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141329219,
                "url": "https://finnhub.io/api/news?id=9d227bb9788bbec12f4ada19baf0f9a5b3442ec7c4b503cb31198016994d61bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, August 26, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences.",
                "category": "company",
                "datetime": 1787774400,
                "headline": "Vertex to Participate in Upcoming September Investor Conferences"
              },
              {
                "id": 141329210,
                "url": "https://finnhub.io/api/news?id=494fc4a7e7e95660a751b27eb0ae630285a8b5d40336969ed3193c07198cabfc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.",
                "category": "company",
                "datetime": 1787751180,
                "headline": "Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock"
              },
              {
                "id": 141329220,
                "url": "https://finnhub.io/api/news?id=2efc1eb2f1504efc935bad39ac81fc43191acc9d8325e302cef134c0b83a88df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
                "category": "company",
                "datetime": 1787736673,
                "headline": "2 Large-Cap Stocks to Research Further and 1 We Question"
              },
              {
                "id": 141329221,
                "url": "https://finnhub.io/api/news?id=bb83f2f0a7c2ff81c357b015f34cc9609eeb516382bc97e2c709c50480540cae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.",
                "category": "company",
                "datetime": 1787584800,
                "headline": "Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide"
              },
              {
                "id": 141270357,
                "url": "https://finnhub.io/api/news?id=c860ce08d4e08f9258062cb8d66f67f20b4b52147ffd6129f0e478139ec5544b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Expert-Sees-Lower-Payments.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).",
                "category": "company",
                "datetime": 1787300370,
                "headline": "Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141279339,
                "url": "https://finnhub.io/api/news?id=8d9cbc0bd104b45cfccc7cbd2c068ed28335b859cc9c4ef376db8c67375a427e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Don't bet against Vertex Pharmaceuticals in cystic fibrosis.",
                "category": "company",
                "datetime": 1787259000,
                "headline": "Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead"
              },
              {
                "id": 141279340,
                "url": "https://finnhub.io/api/news?id=155b9bfb8c208e5ddbce0b12f61eae388a3c391b302784352be725c1e6ca15da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.",
                "category": "company",
                "datetime": 1787213930,
                "headline": "Are Wall Street Analysts Bullish on Vertex Stock?"
              },
              {
                "id": 141265012,
                "url": "https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...",
                "category": "company",
                "datetime": 1787139000,
                "headline": "HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"
              },
              {
                "id": 141279349,
                "url": "https://finnhub.io/api/news?id=5023715a3073c930cbeb889de0d9f0c715e9eb1a27489a9f88dc6339148f07f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "ANT survey delivers a 3D subsurface view that reinforces the Robinsons River geological model and de-risks the next stage of technical workVANCOUVER, British Columbia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce the final results of the Ambient Noise Tomography (“ANT”) survey completed at the Company's 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south",
                "category": "company",
                "datetime": 1787058000,
                "headline": "Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt Project"
              },
              {
                "id": 141279350,
                "url": "https://finnhub.io/api/news?id=c16319e9e5a0594ce94d91a58aae67103c60bf48c8111a1e761a7abb904d849e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.",
                "category": "company",
                "datetime": 1787050653,
                "headline": "3 Cash-Producing Stocks on Our Watchlist"
              },
              {
                "id": 141279342,
                "url": "https://finnhub.io/api/news?id=54e185545576cdb9dc6d734866d58e0390b06540a7324cc4bfacb43aecc1896b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]",
                "category": "company",
                "datetime": 1786751639,
                "headline": "Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?"
              },
              {
                "id": 141279343,
                "url": "https://finnhub.io/api/news?id=121dbbc0dd24c01e2e2cbe20976d9967255da4cc4f625d608de73f25a3e6e9ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...",
                "category": "company",
                "datetime": 1786749229,
                "headline": "Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?"
              },
              {
                "id": 141279344,
                "url": "https://finnhub.io/api/news?id=ad845cd38300618d82185831e5a6bc71375dd3819365cbdfe4d132fbc0e16813",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The drugmaker should significantly mitigate its most important risk as it develops new products.",
                "category": "company",
                "datetime": 1786742400,
                "headline": "Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More"
              },
              {
                "id": 141279351,
                "url": "https://finnhub.io/api/news?id=68de4dec7cef46611e52bc7bd83708d22013031b64ec4eddd23a06dc1e657631",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurchase program. See our latest analysis for Vertex Pharmaceuticals. The latest updates on guidance and buybacks come after a solid run in Vertex Pharmaceuticals' stock, with a 90 day share price return of 18.19% and a 1 year total shareholder return of 31.48%. This suggests momentum has been...",
                "category": "company",
                "datetime": 1786741725,
                "headline": "Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance"
              },
              {
                "id": 141278992,
                "url": "https://finnhub.io/api/news?id=dd9febaaffadd17c6453617b941b5caf27cdeb0d05ef7fba593bec5de3ada72d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...",
                "category": "company",
                "datetime": 1786730820,
                "headline": "BofA biotech scorecard: Two buys and odd one out"
              },
              {
                "id": 141219761,
                "url": "https://finnhub.io/api/news?id=da70f751bbe83141d4f27ef4146624b19996919da2578c396c2740a8e6ab5c54",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1786708843,
                "headline": "$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141216339,
                "url": "https://finnhub.io/api/news?id=c3f0aff57d50e4a1dd7a3be345d26477178a91b70e18cd1e6169d1e527dc0954",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203426973/image_2203426973.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX stock is a Buy.",
                "category": "company",
                "datetime": 1786700403,
                "headline": "Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)"
              },
              {
                "id": 141205416,
                "url": "https://finnhub.io/api/news?id=f9ed0860d21fac5b45889bb5f7d101977f12066b6c9bab95f6a065bf9ebbfa7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.",
                "category": "company",
                "datetime": 1786628127,
                "headline": "Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public"
              },
              {
                "id": 141201319,
                "url": "https://finnhub.io/api/news?id=53aa7945d94041f79fc3c71da1078689d1f51f26eefe2f5010464d79b2c6af29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid",
                "category": "company",
                "datetime": 1786546972,
                "headline": "Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says"
              },
              {
                "id": 141201320,
                "url": "https://finnhub.io/api/news?id=94ae668ac83f9d0c31f3ea05ec0b9d4f8d9080150624d1764bb6bc404342d9d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […]",
                "category": "company",
                "datetime": 1786506091,
                "headline": "One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses"
              },
              {
                "id": 141201321,
                "url": "https://finnhub.io/api/news?id=6e1eb33508d1e98d3f2908639df7e4bb95e526c95178197694a844bc74661f7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to “the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,” while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK a",
                "category": "company",
                "datetime": 1786498882,
                "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call"
              },
              {
                "id": 141195154,
                "url": "https://finnhub.io/api/news?id=3df760a6590509c410b1316b0c369b2cdec8dbbe87802b2bd472f31783084fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.",
                "category": "company",
                "datetime": 1786456860,
                "headline": "4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year"
              },
              {
                "id": 141181019,
                "url": "https://finnhub.io/api/news?id=25154402fb3d0f222a8033f7866218d6e3ae8c5b8861a9206afa0c14ca55b514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Revenue hit $3.3 billion with guidance raised on strong newer product growth.",
                "category": "company",
                "datetime": 1786411788,
                "headline": "Vertex (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141177336,
                "url": "https://finnhub.io/api/news?id=33fd1ad98365e1c3dbe7cfb12732e37392475fc9a30b95ecb5247d60db37ef4c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1786388701,
                "headline": "Discover which S&P500 stocks are making waves on Monday."
              },
              {
                "id": 141176731,
                "url": "https://finnhub.io/api/news?id=f952c743779714457b4eaa6ff9b23dc5fe72cec6eb0b9823761ee130a6bb028f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.",
                "category": "company",
                "datetime": 1786382317,
                "headline": "SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?"
              },
              {
                "id": 141175993,
                "url": "https://finnhub.io/api/news?id=591168258f393e68563e6da9dea3f941c18dfd48941990aa7fa198e9025a1e5b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1786379701,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 141176732,
                "url": "https://finnhub.io/api/news?id=bd21004d940cdf0607d4305d000bc04b7354225c4f16c854cd15d938f7a4a3e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.",
                "category": "company",
                "datetime": 1786377660,
                "headline": "Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low"
              },
              {
                "id": 141175444,
                "url": "https://finnhub.io/api/news?id=345e622f9b0fd39685338ae62271fcae679f190bddb55d205a2d0875784c7044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Sionna's disappointing trial removes an immediate competitive threat to the franchise generating most of Vertex's revenue.",
                "category": "company",
                "datetime": 1786377337,
                "headline": "Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails"
              },
              {
                "id": 141175445,
                "url": "https://finnhub.io/api/news?id=ded9ed4f3587c20b78610c4ba38b8ecf5e094890c470cb2c855d3017e81055fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex’s efforts to broaden its pipeline while easing pressure on its core franchise. We’ll now examine how...",
                "category": "company",
                "datetime": 1786374853,
                "headline": "Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?"
              },
              {
                "id": 141175245,
                "url": "https://finnhub.io/api/news?id=a973147764263f3bdc864ad125bd056f1b6a36b2ab0a6f63d654ad0875da6be9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.",
                "category": "company",
                "datetime": 1786371120,
                "headline": "This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News."
              },
              {
                "id": 141174376,
                "url": "https://finnhub.io/api/news?id=6b4e91291819cf3182cb35b176bf378d8c88e994c518a2edd32e1635e1722681",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.",
                "category": "company",
                "datetime": 1786368173,
                "headline": "Why Vertex Pharma Popped, As A Key Rival Plummeted 90%"
              },
              {
                "id": 141173955,
                "url": "https://finnhub.io/api/news?id=8f8a6c94e14cda994096b4ea274ea3ef41e64e688ce7867132f30f540487144b",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786365301,
                "headline": "Get insights into the top movers in the S&P500 index of Monday's pre-market session."
              },
              {
                "id": 141176733,
                "url": "https://finnhub.io/api/news?id=e621a61ac2fd6f06e6f8dfde3327b9a465a9d264ddc5f3496d75a321a713b950",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.",
                "category": "company",
                "datetime": 1786364579,
                "headline": "Sionna cystic fibrosis drug fails key trial, removing threat to Vertex"
              },
              {
                "id": 141163533,
                "url": "https://finnhub.io/api/news?id=3b7a86f6ceb88fe11df34224171d2e64d74b5e8b7d5f7a718f923ea58fe91d9c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Tweedy Browne’s Q2 2026 13F: $1.32B portfolio, top holdings & new Zoetis stake, plus trims/exits and concentration insights—read now.",
                "category": "company",
                "datetime": 1786229949,
                "headline": "Tracking Tweedy Browne Portfolio - Q2 2026 Update"
              },
              {
                "id": 141150935,
                "url": "https://finnhub.io/api/news?id=f30205fda5e3671faae31aaf11b68289bc37bc3003af8d9080eae74361b10542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "This risk is weighing on the stock.",
                "category": "company",
                "datetime": 1786126800,
                "headline": "Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?"
              },
              {
                "id": 141148212,
                "url": "https://finnhub.io/api/news?id=f1429036e90b90226a0f1548de75810532846ed909768a41040c55c430c961bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.",
                "category": "company",
                "datetime": 1786117197,
                "headline": "What Insmed Stock's Premium Is Actually Buying"
              },
              {
                "id": 141135446,
                "url": "https://finnhub.io/api/news?id=fd1d07072af0353df58d8c6462fe44867241410e634aa7fe7a706972fa6edc43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "IONQ posts a wider-than-expected Q2 loss but tops revenue estimates, raises its 2026 revenue outlook and sees shares rise after the results.",
                "category": "company",
                "datetime": 1786027140,
                "headline": "IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises"
              },
              {
                "id": 141134178,
                "url": "https://finnhub.io/api/news?id=d3341145831fa1164ba72987649fc3f9cde6dfde5df1d47e24be44aed8cc7b65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Study confirms western salt structure, identifies an eastern exploration target and establishes a staged technical pathway for further evaluationVANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release dated July 16, 2026, that it has received the final technical study prepared by Lonquist Field Service (Canada), ULC (“Lonquist”) for the Company’s Robinson",
                "category": "company",
                "datetime": 1786017600,
                "headline": "Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project"
              },
              {
                "id": 141131676,
                "url": "https://finnhub.io/api/news?id=42acecf7bad1baa7ec04cb7ac59418a1c1004daf4cddd4cce6da65363ef901db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.",
                "category": "company",
                "datetime": 1785992501,
                "headline": "AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ..."
              },
              {
                "id": 141129231,
                "url": "https://finnhub.io/api/news?id=dcdf3ce3fb9a9978376d50e78da86431a8757aa1e827d9ec985228c198f4b841",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol",
                "category": "company",
                "datetime": 1785967428,
                "headline": "AbCellera Biologics Q2 Earnings Call Highlights"
              },
              {
                "id": 141128774,
                "url": "https://finnhub.io/api/news?id=2a2a2d7e0c3b0c4acf97cdb30edff26305271e2d709137a8518fb82aaeb34cfe",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Truist Securities  analyst Danielle Brill   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.",
                "category": "company",
                "datetime": 1785938692,
                "headline": "Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565"
              },
              {
                "id": 141120403,
                "url": "https://finnhub.io/api/news?id=f62b2e86c4216e2bda2377255cef430a7f277cbdefbb4b3b2c17c9278e69b758",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc",
                "category": "company",
                "datetime": 1785927600,
                "headline": "Entrada Therapeutics Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141121678,
                "url": "https://finnhub.io/api/news?id=5248f37b608df4175afdacfec21505a887b9d7e62e088904934c0a4a097c8b4d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288169175/image_2288169175.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.",
                "category": "company",
                "datetime": 1785924544,
                "headline": "CRISPR: \"Strong Buy\" CASGEVY Sales Growth And In Vivo Expansion With CTX310"
              },
              {
                "id": 141128775,
                "url": "https://finnhub.io/api/news?id=4a00fc07417e00a900782dede2c3227b5bb2ffd5494048eb5e0a007a66482462",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Barclays  analyst Eliana Merle   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.",
                "category": "company",
                "datetime": 1785922255,
                "headline": "Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617"
              },
              {
                "id": 141111807,
                "url": "https://finnhub.io/api/news?id=e47001faa115166263a442f28230abdba42b95d19b8edb04e4fd9ecec1553469",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa",
                "category": "company",
                "datetime": 1785863115,
                "headline": "Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says"
              },
              {
                "id": 141111808,
                "url": "https://finnhub.io/api/news?id=1779ffa16d4cf28c1b259ac324be9f15ee814476b807b5bf97951a8231ca3e17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength",
                "category": "company",
                "datetime": 1785859337,
                "headline": "Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says"
              },
              {
                "id": 141110155,
                "url": "https://finnhub.io/api/news?id=ab934a24772cacbc2444176e33fe2e26a3432801ece501642cda46733319fe6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment.",
                "category": "company",
                "datetime": 1785855630,
                "headline": "How Vertex Regained Its Footing On A Competitor's Bullish Report"
              },
              {
                "id": 141111809,
                "url": "https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.",
                "category": "company",
                "datetime": 1785855420,
                "headline": "VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"
              },
              {
                "id": 141110509,
                "url": "https://finnhub.io/api/news?id=f6f657f73b56d365c3988923bf6a3d9124e87491e39b6391d0a32defb58016c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.",
                "category": "company",
                "datetime": 1785855360,
                "headline": "CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates"
              },
              {
                "id": 141110156,
                "url": "https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.",
                "category": "company",
                "datetime": 1785852000,
                "headline": "VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"
              },
              {
                "id": 141120404,
                "url": "https://finnhub.io/api/news?id=536ca1939192aa75d5e6bab55534f6b569982fd11bc66824814b4cc31c74a4a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785846600,
                "headline": "Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141128776,
                "url": "https://finnhub.io/api/news?id=a0e8acf95ce40887b103881fce5237ca4516cca5aecd8d5b7c448a54203438f4",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.",
                "category": "company",
                "datetime": 1785846489,
                "headline": "TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550"
              },
              {
                "id": 141111811,
                "url": "https://finnhub.io/api/news?id=e0958b66343c41ec1dc90eccdc735fecb25accfdb235add8df6547d345ab61de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics \"looms large\" over Vertex.",
                "category": "company",
                "datetime": 1785845940,
                "headline": "Vertex’s biggest overhang: a rival 50 times smaller"
              },
              {
                "id": 141107841,
                "url": "https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...",
                "category": "company",
                "datetime": 1785841838,
                "headline": "Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"
              },
              {
                "id": 141107179,
                "url": "https://finnhub.io/api/news?id=06027c260ce9de9f61eb87edc3fd3f074dda0e76b30bcca2da7b0e57104fa68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...",
                "category": "company",
                "datetime": 1785834837,
                "headline": "Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands"
              },
              {
                "id": 141110584,
                "url": "https://finnhub.io/api/news?id=83f00ed155351fa091931ebd6f19d490a2410a74beb0fca26cc0781a757d8552",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.",
                "category": "company",
                "datetime": 1785831893,
                "headline": "Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595"
              },
              {
                "id": 141107416,
                "url": "https://finnhub.io/api/news?id=79c24c254426f5197e92c42652e8d662216c9656ed34db5290a7b518a70f7c0b",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1785826663,
                "headline": "Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story"
              },
              {
                "id": 141106171,
                "url": "https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.",
                "category": "company",
                "datetime": 1785820106,
                "headline": "Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."
              },
              {
                "id": 141105354,
                "url": "https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...",
                "category": "company",
                "datetime": 1785798598,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141104289,
                "url": "https://finnhub.io/api/news?id=c7c1bac8a4be7e1bca887af4abc9e92a06d03ce636155d166171dc8851c4e126",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra",
                "category": "company",
                "datetime": 1785798229,
                "headline": "Vertex Pharmaceuticals Q2 Earnings Call Highlights"
              },
              {
                "id": 141105291,
                "url": "https://finnhub.io/api/news?id=cd71711e25cb163c9f05f483851c9f5b6b7eb81c55fa46d409773ec5676efefb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "2026-08-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785798079,
                "headline": "Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141104290,
                "url": "https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785792601,
                "headline": "Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141104291,
                "url": "https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785792003,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"
              },
              {
                "id": 141103107,
                "url": "https://finnhub.io/api/news?id=98a2abcf301231bc0d0aaead7b8926e9c78fdfcb82c76cbbb0cc6e889ba5bb06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.",
                "category": "company",
                "datetime": 1785790435,
                "headline": "Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason"
              },
              {
                "id": 141103108,
                "url": "https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785789407,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"
              },
              {
                "id": 141103109,
                "url": "https://finnhub.io/api/news?id=c2b5656a468d8791f71fe09a62a59cf02bfd34ac2e88a2aafd4178787e8d1233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumor",
                "category": "company",
                "datetime": 1785787500,
                "headline": "Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update"
              },
              {
                "id": 141103110,
                "url": "https://finnhub.io/api/news?id=b906634ef71b39efd517bbbaafd8f51cefd4da9cb3e99c193c693beb458b10fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, August 03, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.",
                "category": "company",
                "datetime": 1785787260,
                "headline": "Vertex Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141102404,
                "url": "https://finnhub.io/api/news?id=939a925a360f140b82437bcf1c066f9578c7f6d8d02242dd6344b422c5f7a75f",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.",
                "category": "company",
                "datetime": 1785772904,
                "headline": "Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est"
              },
              {
                "id": 141102405,
                "url": "https://finnhub.io/api/news?id=d851715324594ca0a83a36932e5f194d1100c4a171088992edaa84adad7f327d",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last",
                "category": "company",
                "datetime": 1785772886,
                "headline": "Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate"
              },
              {
                "id": 141101633,
                "url": "https://finnhub.io/api/news?id=210dc9eadb0f1e641b405b20d701188a86b5d7a5db961e15cc5ee67a2573203c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231767274/image_2231767274.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Big Tech's earnings reports laid bare a growing divide in the market's appetite for AI spending. Investors now focus on results from industrials, health care, consumer staples/discretionary.",
                "category": "company",
                "datetime": 1785766800,
                "headline": "Divided Tech, Divided Fed: Navigating AI Capex Scrutiny And Mixed Macro Signals"
              },
              {
                "id": 141098887,
                "url": "https://finnhub.io/api/news?id=48d0b35462c58b56f76fb282a857a48a7324ea7d8a8bec1032ce82a8f07a63bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the",
                "category": "company",
                "datetime": 1785755481,
                "headline": "Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 141099604,
                "url": "https://finnhub.io/api/news?id=0b813f41b7078cecf12b4aafa9a2ca131b75aa021fa9c19c50adbd14d08635cb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/TysonFoods.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.",
                "category": "company",
                "datetime": 1785724052,
                "headline": "Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday"
              },
              {
                "id": 141100201,
                "url": "https://finnhub.io/api/news?id=bad502596ada943e824fa1a41cadb663072846cc663445ce8eab7c42d8dbcca9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.",
                "category": "company",
                "datetime": 1785723704,
                "headline": "Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone"
              },
              {
                "id": 141091494,
                "url": "https://finnhub.io/api/news?id=fab83185dfc322c5138a32b43f26849a509ecd83026c58227dad50ddfd0cb7aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785645417,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 76,
            "discarded_article_count": 62
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1235076.6666666667,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1029000,
              "avg_vol_20": 1200290,
              "avg_vol_30": 1235076.6666666667,
              "range_pct_10": 0.09762726446678688,
              "range_pct_20": 0.16561372711328415,
              "range_pct_30": 0.16655035015976097,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8331466602613062,
              "dist_to_20d_high": 0.020101099533912807,
              "down_shrink_days": 4,
              "breakout_level_20d": 555.69,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.586172676149521
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.474032084256516,
              "turnoverUsdM": 651.9581761061601,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.VRTX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 517.5768,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.6,
            "stop_loss_percent": 4.9,
            "take_profit_price": 587.0005,
            "target_multiplier": 2.2,
            "technical_strength": 2.15,
            "take_profit_percent": 7.8
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.5763740595029545,
          "stopLossPercent": 4.948064168513032,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 13.4716,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.47
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 54.12
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0188
    },
    "kdj": {
      "d": 77.02,
      "j": 53.98,
      "k": 69.34,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 40.61
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 19114608,
      "recentSlope": 177770.8,
      "previousSlope": 467510
    },
    "rsi": 56.76,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 531.3817,
      "position": "SAR喺價下",
      "distancePct": 2.41,
      "previousTrend": "上升"
    },
    "ma50": 502.4064,
    "macd": {
      "macd": 15.768400554108894,
      "trend": "強烈看漲",
      "signal": 15.207408974094761,
      "histogram": 0.5609915800141323
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 522.5111,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 19
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.01,
      "score": 6,
      "avgVolume": 1184630,
      "currentVolume": 1197308
    },
    "derived": {
      "ma20": 525.536,
      "ma50": 502.4064,
      "prevClose": 541.69,
      "avgVolume10": 1037611,
      "avgVolume20": 1184630,
      "changePercent": 0.52,
      "avgVolumeForScore": 1184630
    },
    "ma_cross": {
      "ma20": 525.536,
      "ma50": 502.4064,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 521.846,
      "prevMa50": 500.5486,
      "spreadPct": 4.6,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 478.0385,
      "upper": 573.0335,
      "position": "上半部"
    },
    "rsi_short": 41.28,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.01
    }
  }
}

Raw metrics JSON

 
{
  "close": 544.52,
  "volume": 1197308,
  "changePercent": 0.52
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.